Hydrogel-Based Drug Delivery System Market Analysis – Global Industry Size, Share, Trends and Forecast 2022 - 2030
The Global Hydrogel-Based Drug Delivery System Market size accounted for USD 6,415 Mn in 2021 and is estimated to reach USD 12,357 Mn by 2030, with a CAGR of 7.6% from 2022 to 2030.
Hydrogels have a variety of unique properties in terms of porosity, mechanics, interfacial dynamics, and biological responses, making them ideal for a variety of applications. The hydrogels' versatility and diversity extend beyond targeted drug delivery to wound dressings, contact lenses, and tissue engineering, to name a few applications. One key application is drug delivery systems. Hydrogels are made up of 90% water and are extremely porous to allow for drug delivery and controlled release. Hydrogel delivery systems have been used in clinical trials and can improve therapeutic drug delivery outcomes. Hydrogels can control the spatial and temporal withdrawal of a variety of therapeutic agents, such as small-molecule drugs, macro-molecular drugs, and cells. Because of their versatile controllable degradability, physical properties, and ability to protect labile drugs from degradation, hydrogels provide as a framework on which numerous physiochemical reactions with the encapsulated drugs arise to control drug release.
Hydrogel-based Drug Delivery System Market Dynamics
Market Growth Drivers:
- High drug loading capacity
- Easiness of manufacture and self-application quality
- Rise in demand for controlled release of drug delivery systems
Market Restraint:
- High cost of hydrogel
- Compatibility issues with a small number of medicines
Market Opportunities:
- Increasing approval of new hydrogel-based products
- Surging R&D activities related to drug delivery systems
Report Coverage
| Market | Hydrogel-Based Drug Delivery System Market |
| Market Size 2021 | US$ 6,415 Mn |
| Market Forecast 2030 | US$ 12,357 Mn |
| CAGR | 7.6% During 2022 - 2030 |
| Analysis Period | 2018 - 2030 |
| Base Year | 2021 |
| Forecast Data | 2022 - 2030 |
| Segments Covered | By Polymer Origin, By Delivery Route, And By Geography |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | Ashland, Bausch and Lomb, Johnson & Johnson, Micropore Technologies, Medtronic, Neurelis, Inc., Ocular Therapeutix, Inc, ProLynx Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
| Customization Scope |
10 hrs of free customization and expert consultation |
The surging adoption of supramolecular hydrogels is one of the current trends in the hydrogel-based drug delivery system market. Supramolecular hydrogels are made up of non-covalent intermolecular interactions that hold two or more molecular entities together. The non-covalent cross-linking of these hydrogels is a very appealing feature because it avoids the issues of limited drug loading potential and drug administration for use only as implantable, which would be the only option with a covalently cross-linked network. Thus, the high drug loading capacity of hydrogel is fueling the industry demand in drug delivery applications.
Rising demand for controlled release of drug delivery has created a buzz for hydrogel in the industry. Systemic toxicity and repeated dosing are two issues that plague traditional drug delivery methods. Hydrogels provide convenient drug delivery vehicles that minimize these drawbacks while maximizing the drug's therapeutic benefits. Hydrogels emerge as very efficient drug delivery systems due to their intricately controllable physical properties that grant enormous, controlled drug release characteristics and the benefits they offer for instable drug protection from degradation.
However, the high cost of hydrogels and compatibility issues with a smaller number of medicines are some of the aspects that are creating hurdles for market growth. On the other hand, significant research & development activities, as well as technological advancements related to drug delivery systems, are some of the future opportunities that are boosting the hydrogel-based drug delivery system market revenue. Hydrogel modifications have made significant progress in terms of improving shape memory and reversibility after prolonged stress. The construction of supramolecular hydrogels with tunable mechanical properties and multi-shape memory effects, for example, advances the thermal responsiveness behavior of hydrogels.
Hydrogel-Based Drug Delivery System Market Segmentation
Polymer origin, delivery route, and geography are all used to segment the worldwide hydrogel-based drug delivery system market.
Market by Polymer Origin
- Natural
- Hybrid
- Synthetic
On the basis of polymer origin, the natural segment achieved maximum hydrogel-based drug delivery system market share in 2021. Natural polymers have been studied extensively in medical fields such as tissue engineering and drug delivery. This is attributable to the fact that they are biodegradable and do not cause inflammation in the body. Natural polymers have also been demonstrated to be conducive to cell growth and have a close resemblance to the tissue matrix in tissue engineering. Some of the polymers used in the manufacturing of natural hydrogel include proteins such as gelatin, collagen, and lysosome; and polysaccharides such as hyaluronic acid, chitosan, and alginate. However, the synthetic segment is expected to achieve the fastest growth rate throughout the coming years.
Market by Delivery Route
- Subcutaneous
- Oral Cavity
- Ocular
- Topical
- Others
In 2021, ocular delivery generated the maximum revenue in the delivery route segment, due to their primary application in contact lenses. Furthermore, the delivery of ocular drugs is fraught with difficulties. These are caused by the cornea, conjunctiva, blinking reflex, and nasolacrimal drainage system, among other tissue barriers and defense mechanisms found in the eye. As a result, many traditional ophthalmic preparations, such as eye drops, have low bioavailability profiles, are quickly removed from the administration site, and thus deliver drugs ineffectively. Hydrogels have been studied as a delivery system that may be able to address some of these issues. These have been developed as stand-alone systems or in combination with other technologies like nanoparticles. Meanwhile, the subcutaneous segment is anticipated to witness the fastest CAGR throughout the forecast timeframe from 2022 to 2030.
Hydrogel-Based Drug Delivery System Market Regional Overview
North America
· U.S.
· Canada
Europe
· U.K.
· Germany
· France
· Spain
· Rest of Europe
Latin America
· Mexico
· Brazil
· Rest of Latin America
Asia-Pacific
· India
· Japan
· China
· Australia
· South Korea
· Rest of Asia-Pacific
Middle East & Africa
· GCC Countries
· South Africa
· Rest of Middle East & Africa
Increasing Number of Product Launches Boosts the North America Hydrogel-Based Drug Delivery System Market Growth
According to regional analysis, North America held the largest market share during the forecast period. This is due to the presence of local hydrogel suppliers, frequent product launches, as well as the presence of cost-effective reimbursement that includes the cost of modern therapies. Furthermore, the surging number of studies to enhance hydrogel-based protein delivery and increasing expenditure on hydrogel-based drug delivery systems are other two factors driving the North American hydrogel-based drug delivery system industry. Asia-Pacific, on the other hand, is expected to grow at the fastest rate during the forecast period due to the increased adoption of hydrogel-based systems for effective drug delivery processes.
Market Players
Some of the top hydrogel-based drug delivery system companies offered in the professional report include Ashland, Bausch and Lomb, Johnson & Johnson, Micropore Technologies, Medtronic, Neurelis, Inc., Ocular Therapeutix, Inc, ProLynx Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.
Frequently Asked Questions
How big was the market size of global hydrogel-based drug delivery system market in 2021?
The estimated value of global hydrogel-based drug delivery system market in 2021 was accounted to be USD 6,415 Mn.
What will be the projected CAGR for global hydrogel-based drug delivery system market during forecast period of 2022 to 2030?
The projected CAGR of hydrogel-based drug delivery system market during the analysis period of 2022 to 2030 is 7.6%.
Which are the prominent competitors operating in the market?
The prominent players of the global hydrogel-based drug delivery system market involve include Ashland, Bausch and Lomb, Johnson & Johnson, Micropore Technologies, Medtronic, Neurelis, Inc., Ocular Therapeutix, Inc, ProLynx Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.
Which region held the dominating position in the global hydrogel-based drug delivery system market?
North America held the dominating share for hydrogel-based drug delivery system during the analysis period of 2022 to 2030.
Which region exhibited the fastest growing CAGR for the forecast period of 2022 to 2030?
Asia-Pacific region exhibited fastest growing CAGR for hydrogel-based drug delivery system during the analysis period of 2022 to 2030.
What are the current trends and dynamics in the global hydrogel-based drug delivery system market?
High drug loading capacity, easiness of manufacture and self-application quality, and rise in demand for controlled release drug delivery systems drives the growth of global hydrogel-based drug delivery system market.
By segment polymer origin, which sub-segment held the maximum share?
Based on polymer origin, natural segment held the maximum share for hydrogel-based drug delivery system market in 2021.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
